Albireo Pharma Inc BAIIA
Quel est le BAIIA de Albireo Pharma Inc?
Le BAIIA de Albireo Pharma Inc est -$112.20
Quelle est la définition de BAIIA?
Le BAIIA est le bénéfice avant intérêts, impôts, dépréciations et amortissements d’une entreprise. Il s’agit d’une mesure comptable calculée à partir du bénéfice net avant de sustraire les intérêts, impôts et amortissements d’une entreprise, comme mesure de la rentabilité opérationnelle courante de l’entreprise.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
BAIIA des entreprises dans Health Care secteur sur NASDAQ par rapport à Albireo Pharma Inc
Que fait Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Entreprises avec baiia similaire à Albireo Pharma Inc
- Jianzhong Construction Development a BAIIA de -¥113.30
- Kadmon Inc a BAIIA de -$113.20
- Geron a BAIIA de -$113.06
- Pliant Therapeutics a BAIIA de -$112.61
- Avalara Inc a BAIIA de -$112.60
- Christine International a BAIIA de -¥112.46
- Albireo Pharma Inc a BAIIA de -$112.20
- Kadmon a BAIIA de -$112.01
- Inhibrx a BAIIA de -$111.79
- Apollo Future Mobility a BAIIA de -HKD$111.73
- Ballard Power Systems a BAIIA de -$111.66
- Housing Development and Infrastructure a BAIIA de -₨111.53
- ALX Oncology a BAIIA de -$111.40